Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer
Volunteer to participate in the trial and sign the informed consent
Pathologically or cytologically confirmed cervical cancer
aged 18 years or older
ECOG performance score 0-1
Participants with other diseases of hematopoietic system, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome
Participants with thrombocytopenia occurred within the last 6 months due to causes other than CTIT, including but not limited to chronic liver disease, hypersplenism, infection
Bone marrow invasion or metastasis
History of severe cardiovascular disease within the last 6 months, such as congestive heart failure (NYHA heart function score III-IV), arrhythmias known to increase the risk of thromboembolism such as atrial fibrillation, after coronary stenting, angioplasty, and para-coronary transplantation, etc
Single group
herombopag
Drugreceive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
Proportion of participants with PLT <75×109/L after the use of herombopag
number of participants with PLT \<75×109/L/ all participants
minimum value of platelet after chemotherapy
minimum value of platelet of every participants after chemotherapy for every participants
Change from baseline in PLT count minimum value
absolute value change from the maximum or minimum of platelet to baseline for every participants
Median duration of PLT <75×109/L
the days during the PLT \<75×109/L of every participants
Median time to recovery of PLT to ≥100×109/L
the days during the PLT \>100×109/L of every participants
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
